slide deck (pdf) - CME Outfitters
slide deck (pdf) - CME Outfitters slide deck (pdf) - CME Outfitters
Alpha – Blockers Inhibit α1-adrenergic mediated contraction of prostate smooth muscle, thereby relieving bladder outlet obstruction Non - Uroselective Terazosin 1, 2, 5, 10 mg daily Doxazosin 1, ,2, 4, 8 mg daily Uroselective Tamsulosin 0.4 mg daily Alfuzosin 10 mg daily Silodosin 8 mg daily § Poten?al side effects (decreased incidence with uroselec?ve agents) – Asthenia, fa?gue, dizziness – Postural hypotension – Conges?on, rhini?s – Abnormal ejacula?on Physician’s Desk Reference, 64 ed. Montvale, NJ:Thomson PDR; 2010. Lepor H. Rev Urol. 2007;9:181-190. PMID: 18231614 Roehrborn CG. Rev Urol. 2009;11(Suppl 1):S1-8. PMID: 20126606
Clinical Management Step2b: Phosphodiesterase 5 Inhibitors (PDE5i) Single medication therapy with a PDE5-I is appropriate for the symptomatic patient who has identified bother and has a PSA of < 1.5 ng/ml. The potential impact of this therapy on male sexual function should be considered ! New as a treatment for BPH-LUTS ! It is believed that the PDE5i increase the signaling of the NO/cGMP pathway, which reduces smooth muscle tone in the lower urinary tract ! It is not believed that use of a PDE5i will reduce progression of prostate growth Roehrborn CG, et al. J Urol. 2008;180(4):1228-1234. PMID: 18722631. Rosenberg MT, et al. Publication Pending.
- Page 1 and 2: Gaining Ground in Men’s Genitouri
- Page 3 and 4: Accreditation This program has been
- Page 5 and 6: Learning Objectives ! Explain the s
- Page 7 and 8: Matt T. Rosenberg, MD Disclosures S
- Page 9 and 10: Disclosures ! Faculty of this CE ac
- Page 11 and 12: Get Social with Us CMEOutfitters.co
- Page 13 and 14: Georgia Association of Physician As
- Page 15 and 16: Matt T. Rosenberg, MD Disclosures S
- Page 17 and 18: In what percentage of your patients
- Page 19 and 20: Function of the Prostate Normal Fun
- Page 21 and 22: Benign Prostatic Hyperplasia ! A co
- Page 23 and 24: Predominant Symptoms ! The enlarged
- Page 25 and 26: Definition of OAB International Con
- Page 27 and 28: How to differentiate the etiology o
- Page 29 and 30: Common Comorbidities in BPH-LUTS Co
- Page 31 and 32: Audience Response Question Fact: ED
- Page 33 and 34: BPH-LUTS and ED Common Pathophysiol
- Page 35 and 36: What to Keep in Mind in the Evaluat
- Page 37 and 38: The Evaluation of LUTS: History, Ph
- Page 39 and 40: Medications Can Cause or Exacerbate
- Page 41 and 42: Laboratory Tests ! Urinalysis ! Inf
- Page 43 and 44: Audience Response Question The most
- Page 45 and 46: The Purpose of the Voiding Diary !
- Page 47 and 48: Rosenberg MT, et al. Publication Pe
- Page 49 and 50: STEP 1: Informed Surveillance If th
- Page 51: Clinical Management Step2a: Alpha B
- Page 55 and 56: Rosenberg MT, et al. Publication Pe
- Page 57 and 58: Antimuscarinics - Immediate Release
- Page 59 and 60: ! Dry Mouth ! Constipation ! Headac
- Page 61 and 62: Beta 3 Agonists Drug Mirabegron Dos
- Page 63 and 64: Clinical Management Step3b: Adding
- Page 65 and 66: 5 Alpha Reductase Inhibitors (5ARI)
- Page 67 and 68: Rosenberg MT, et al. Publication Pe
- Page 69 and 70: Clinical Connections: Summary ! Tre
Clinical Management<br />
Step2b: Phosphodiesterase 5 Inhibitors<br />
(PDE5i)<br />
Single medication therapy with a PDE5-I is appropriate for<br />
the symptomatic patient who has identified bother and has a<br />
PSA of < 1.5 ng/ml. The potential impact of this therapy on<br />
male sexual function should be considered<br />
! New as a treatment for BPH-LUTS<br />
! It is believed that the PDE5i increase the signaling of<br />
the NO/cGMP pathway, which reduces smooth<br />
muscle tone in the lower urinary tract<br />
! It is not believed that use of a PDE5i will reduce<br />
progression of prostate growth<br />
Roehrborn CG, et al. J Urol. 2008;180(4):1228-1234. PMID: 18722631.<br />
Rosenberg MT, et al. Publication Pending.
Change language